KCKarel Caca

Karel Caca

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karel Caca has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Julius Mueller

    University of Freiburg Faculty of Medicine, BW, Germany

    12 shared publications
  • Arthur Schmidt

    Department of Gastroenterology, Klinikum Ludwigsburg, Ludwigsburg, Germany; Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    7 shared publications
  • Alexander Meining

    Department of Gastroenterology, University of Ulm, Ulm, Germany

    4 shared publications
  • Benjamin Meier

    Internal Medicine I, Klinikum Ludwigsburg, Ludwigsburg Germany

    4 shared publications
  • Bettina Riecken

    Department of Gastroenterology, Hepatology and Oncology, Hospital of Ludwigsburg, Germany

    4 shared publications
  • Andreas Wannhoff

    Internal Medicine I, Klinikum Ludwigsburg, Ludwigsburg Germany

    3 shared publications

Latest Publications

  • Endoscopic sleeve gastroplasty for severe obesity by full-thickness suturing using the GERDX device

    by Andreas Wannhoff, Christopher Hofmann, Benjamin Meier, Dieter Birk, Karel Caca

    Obesity is an increasing health problem worldwide. Endoscopic therapies have emerged as treatment option in addition to lifestyle modification and bariatric surgery. One possible endoscopic approach is to reduce the size of the stomach [1] [2]. This approach has been demonstrated to be feasible and efficient using different endoscopic suturing devices [3] [4]. The GERDX device (G-Surg GmbH, Seeon-Seebruck, Germany) allows full-thickness suturing in the upper gastrointestinal tract and was originally used for endoscopic antireflux therapy [5]. The transmural sutures have proven to be durable and to remain in situ even after long follow-up. In this 41-year old woman, who suffered from severe obesity (168 cm, 121 kg, body mass index [BMI] 42.9 kg/m2), we aimed to use the GERDX device to perform an endoscopic sleeve gastroplasty. The device was inserted into the stomach and an ultraslim endoscope was introduced through the device’s working channel to provide visualization. Next, the gastric wall was retracted with a tissue retractor and the full-thickness suture was applied. This was repeated 18 times from the fundus to the distal corpus ([Video 1]). This resulted in a markedly reduced stomach volume. Video 1 A new treatment option for obesity. Use of the GERDX device (G-Surg GmbH, Seeon-Seebruck, Germany) for application of transmural sutures in the stomach in order to perform endoscopic sleeve gastroplasty. The procedure was performed under general anesthesia and peri-interventional antibiotic therapy was initiated. The gastric volume reduction was successfully performed using the GERDX device ([Fig. 1]) and no procedure-related complications occurred. The next day a control endoscopy was performed, which confirmed the volume reduction and showed no signs of bleeding or perforation. A contrast swallow test confirmed the sleeve configuration of the stomach ([Fig. 2]). A normal diet was resumed within days and the patient was discharged on Day 5 without any further complications. After 8 weeks, the patient had lost 12 kg of weight, resulting in a change in BMI of – 4.3 kg/m2 or a percent excess weight loss of 24.0 %. Endoscopic sleeve gastroplasty using the GERDX device was feasible, safe, and efficient in this patient. This technique could potentially emerge as a minimally invasive treatment for obesity. Endoscopy_UCTN_Code_TTT_1AO_2AJ


  • Over-the-Scope Clips Are More Effective Than Standard Endoscopic Therapy for Patients With Recurrent Bleeding of Peptic Ulcers

    by Arthur Schmidt, Stefan Gölder, Martin Goetz, Alexander Meining, James Lau, Stefan von Delius, Markus Escher, Arthur Hoffmann, Reiner Wiest, Helmut Messmann, et al.


  • Sa1902 LOW RISK OF APPENDICITIS OR MUCOCELE FOLLOWING FULL THICKNESS RESECTION OF ADENOMAS ARISING FROM THE APPENDICEAL ORIFICE

    by Benjamin Walter, Simone Schmidbaur, Benjamin Meier, Andreas Wannhoff, Alexander Meining, Karel Caca

  • Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis

    by Christoph Klinger, Bettina Riecken, Arthur Schmidt, Andrea De Gottardi, Benjamin Meier, Jaime Bosch, Karel Caca


  • Over-the-scope clip is an effective therapy for postbanding ulcer bleeding after initially successful transjugular intrahepatic portosystemic shunt therapy

    by Oscar Cahyadi, Karel Caca, Arthur Schmidt

    Postbanding ulcer bleeding (PBUB) is a potential deadly complication after esophageal variceal banding (EVB) in patients with portal hypertension, with a reported incidence of 2.6 % – 7.3 % [1]. Various treatment possibilities for PBUB, such as cyanoacrylate injection, self-expandable metal stents, and transjugular intrahepatic portosystemic shunt (TIPS), are commonly applied. Rebleeding from a postbanding ulcer after initially successful TIPS is rare, and no clear treatment algorithm is available. Here, we report on the successful application of an over-the-scope clip (OTSC) to treat a PBUB after successful TIPS not amenable to EVB or hemoclip. A 45-year-old man with a history of alcoholic liver cirrhosis (Child–Pugh stage B and model for end-stage liver disease score 6) underwent EVB and cyanoacrylate injection for bleeding esophageal varices at an external hospital. After recurrent drops in hemoglobin level, which was suspicious for intermittent refractory PBUB not visible on repeated esophagogastroduodenoscopy (EGD), he was referred to our unit for emergency TIPS. The TIPS procedure was uneventful. Thereafter, he had another drop in hemoglobin level. Urgent EGD revealed a spurting PBUB ([Fig. 1a]). Tissue scarring meant that repeat EVB or hemoclipping was not possible. Thus, an OTSC was applied (Type 12/6T; Ovesco Medical, Tübingen, Germany) ([Fig. 1 b]). Hemostasis was achieved immediately ([Fig. 1 c]). Second-look endoscopy revealed stable hemostasis, and the hemoglobin level remained stable during the subsequent clinical course ([Fig. 1 d], [Video 1]). Video 1 A patient with a postbanding ulcer bleeding after initially successful therapy with transjugular intrahepatic portosystemic shunt. Hemostasis was achieved with the application of an over-the-scope clip. No acute rebleeding was observed after extensive irrigation with saline. It should be noted that the use of OTSC in PBUB currently constitutes an off-label application. Hitherto, there is only one report known to us regarding the (off-label) use of OTSC in acute variceal bleeding [2]. Endoscopy_UCTN_Code_TTT_1AO_2AD


  • Efficacy of gemcitabine with erlotinib in rash-positive patients selected according to eligibility for FOLFIRINOX.

    by Michael Haas, Stefan Hubert Boeck, Jens T. Siveke, Michael Schenk, Markus Lerch, Karel Caca, Jens Freiberg-Richter, Ludwig Fischer von Weikersthal, Frank Kullmann, Anke C. Reinacher-Schick, et al.

    4108 Background: The efficacy and safety of gemcitabine + erlotinib has not yet been defined prospectively in patients (pts) with metastatic pancreatic cancer (mPC) selected according to the inclusion criteria defined by Conroy et al. for FOLFIRINOX (e. g. ECOG 0-1, age < 75, bilirubin < 1.5xULN). Methods: In this German phase II trial, 150 pts with histologically confirmed mPC were recruited between July 2012 and July 2015 in 20 centers. If pts showed skin rash of any grade within 4 weeks after start of treatment with gemcitabine (1000 mg/m2 weekly) and erlotinib (100 mg daily), this regimen was continued; rash-negative pts were switched to FOLFIRINOX. The primary study endpoint was the 1-year survival rate in rash-positive pts (hypothesis: ≥40%). Results: Ninety pts who were under treatment with gemcitabine + erlotinib for 4 weeks developed skin rash of any grade: the 1-year survival rate in those pts positive for skin rash was 40.0% (95%CI 29.8-50.9); median overall survival (OS) counted from day of first treatment was 10.1 months (mo) (95%CI 9.0-12.5), progression-free survival (PFS) 3.9 mo (95%CI 3.5-4.9), objective response rate (ORR) and disease control rate (DCR) were 21% and 64%, respectively. Median treatment duration with gemcitabine+erlotinib was 3.7 mo (Range 0.7-17.5). In rash-negative pts who were switched to FOLFIRINOX after 4 weeks of gemcitabine + erlotinib (n = 28) the 1-year survival rate was 46.4% (95%CI 27.5-66.1), median OS 10.6 mo (95%CI 6.6-13.6), median PFS 5.2 mo (95%CI 2.3-7.9) and the corresponding ORR and DCR rates were 29 and 54%, respectively. The rate of salvage therapy was 53% after gemcitabine+erlotinib, mostly consisting of 5-FU-based schemas (42 % 5-FU/folinic acid + irinotecan or oxaliplatin, 38% FOLFIRINOX) and 43% after FOLFIRINOX (all pts received gemcitabine, 67% in combination with nab-paclitaxel). In the Intention To Treat (ITT) population (n = 145) OS was 9.7 mon (95%CI 7.8-10.9). Conclusions: In rash-positive pts deemed fit for FOLFIRINOX first-line treatment with gemcitabine + erlotinib appears effective achieving a one-year-survival rate of 40%. Early switch to FOLFIRINOX was an effective strategy in rash-negative patients. Clinical trial information: NCT01729481.


  • Open Access

    Effective treatment of benign biliary strictures with a removable, fully covered, self‐expandable metal stent: A prospective, multicenter European study

    by Arthur Schmidt, Tilman Pickartz, Markus M Lerch, Fabrizio Fanelli, Fausto Fiocca, Pierleone Lucatelli, Fabrizio Cereatti, Albrecht Hoffmeister, Werner van Steenbergen, Matthias Kraft, et al.

    Background: Temporary placement of removable, fully covered, self‐expandable metal stents (fcSEMS) for treatment of benign biliary strictures (BBS) has been reported to be effective. However, the optimal extraction time point remains unclear and stent migration has been a major concern.Objective: The objective of this study was to evaluate the efficacy and safety of this treatment modality using an fcSEMS with a special antimigration design and prolonged stent indwell time.Methods: We performed a prospective, single‐arm study at six tertiary care centers in Europe. Patients with BBS underwent endoscopic or percutaneous implantation of an fcSEMS (GORE® VIABIL® Biliary Endoprosthesis, W.L. Gore & Associates, Flagstaff, AZ, USA). The devices were scheduled to be removed nine months later, and patients were to return for follow‐up for an additional 15 months.Results: Forty‐three patients were enrolled in the study. Stricture etiology was chronic pancreatitis in the majority of patients (57.5%). All fcSEMS were placed successfully, either endoscopically (76.7%) or percutaneously (23.3%). Stent migration was observed in two patients (5.2%). Primary patency of the SEMS prior to removal was 73.0%. All attempted stent removals were successful. At removal, stricture was resolved or significantly improved without need for further therapy in 78.9% of patients. Stricture recurrence during a follow‐up of two years post‐implant was observed in two patients.Conclusions: Temporary placement of the fcSEMS is a feasible, safe and effective treatment for BBS. The design of the device used in this study accounts for very low migration rates and facilitates easy stent retrieval, even after it has been in place for up to 11 months.